Transpek Inds. — Q3 FY25 earnings call

Call held 21 Feb 2025

Management summary

Transpek Industry Limited reported a sustained performance for the first nine months of FY25 amidst global chemical industry challenges. The company achieved revenue growth driven by existing products and is progressing with new, higher-margin product developments. Despite margin compression, management remains confident in maintaining profitability and expects NSE listing by April end.

Highlights

  • Total revenue for 9M FY25 stood at ₹505.6 crores, reflecting a 12% year-on-year growth.

  • EBITDA for 9M FY25 was ₹90.3 crores, an increase of 7.6% YoY, excluding an exceptional item.

  • EBITDA margins for 9M FY25 were 17.9%, which is 70 basis points lower than 9M FY24.

  • Profit after tax for 9M FY25 was ₹29.5 crores, a decrease of 10.4% YoY.

  • The Polymer segment contributed 58% to the revenue, with International Business accounting for 86% of total revenue.

  • Current capacity utilization is approximately 65%.

  • An exceptional loss of ₹6.9 crores was recorded due to discarding obsolete equipment.

  • NSE listing process is underway and expected to be completed by April end.

Key financials

  1. Revenue ₹505.6 Cr +12%YoY
  2. EBITDA ₹90.3 Cr +7.6%YoY
  3. EBITDA Margin 17.9%
  4. PAT ₹29.5 Cr -10.4%YoY
  5. Exceptional Item (Loss) ₹6.9 Cr

What they filed

Q1 FY27: revenue down 2.1%, net profit down 42.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue163 170 165 154 160 −1%158 −7%148 −10%151 −2%
EBITDA23 24 32 24 27 +18%25 +4%18 −45%20 −16%
Net profit10 11 19 16 13 +32%11 +2%7 −66%9 −43%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Polymer
    58% Revenue Contribution
  • Pharma
    10% Revenue Contribution
  • Specialty
    19% Revenue Contribution
  • International Business
    86% Revenue Contribution
  • Domestic Market
    14% Revenue Contribution
  • North America
    62% International Business Contribution

Capital allocation

medium confidence
  • Debt Debt disclosed
    We remain a very low debt company with a strong balance sheet.

Guidance & targets

New Products

  • New Products Revenue (Non-Acid Chloride) New Products · annually within 2 years · Medium confidence ₹150-200 crores
    If everything goes right, then about 3-4 products when you put together in another 2 years' time, at the completion of 2 years, it would be annually anywhere between Rs. 150 crores-Rs. 200 crores.

    — Bimal Mehta

  • New Products EBITDA Margins New Products · ongoing · Medium confidence 20%
    It would be around EBITDA margins of 20% roughly.

    — Bimal Mehta

  • Kevlar EXO Commercial Production New Products · by January 2026 · High confidence started
    I think it should go on commercial production, large scale commercial production by January 2026.

    — Bimal Mehta

  • Kevlar EXO Impact on Demand New Products · post-Jan 2026 · Medium confidence little more demand
    there will definitely be a little more demand for the raw material that we are supplying when you consider from a percentage input in the Kevlar versus the new Kevlar.

    — Bimal Mehta

Revenue

  • FY26 Revenue Growth Revenue · FY26 · Medium confidence 10%
    We should be largely in the same range as we are this year, maybe about 10% growth.

    — Bimal Mehta

Margin

  • FY26 Margins Margin · FY26 · High confidence maintained
    Yes, largely current margins should be possible to be maintained.

    — Bimal Mehta

Corporate Action

  • NSE Listing Corporate Action · by April end · High confidence completed
    We believe that it should be done by April end

    — Bimal Mehta

Customer Contracts

  • DuPont Contract Renewal Discussions Customer Contracts · next 1-1.5 years · Medium confidence initiated
    Probably about 1-1.5 years' time, the discussion will start on renewal.

    — Bimal Mehta

  • DuPont Contract Volume Sustainability Customer Contracts · until contract ends · High confidence sustained
    But we believe that largely we will maintain what we are supplying until this current contract ends.

    — Bimal Mehta

What to watch in Q4 FY25

NSE Listing Completion

by April end
Current Process initiated, additional documents requested
Target Listing completed

Why it matters

Completion of this long-pending corporate action is expected to improve liquidity and market visibility.

We believe that it should be done by April end

Risks & concerns

  • Global chemical industry challenges and demand softness

    medium

    Demand and consumption in major global markets, particularly China and Europe, have continued to struggle, impacting performance.

    Management acknowledged

  • Volatility in chemical prices

    medium

    Volatility in chemical prices has added to the challenges faced by the industry.

    Management acknowledged

  • Competitive pressures and slow export demand

    medium

    Aggressive pricing, stiff competition, and slow demand in the export market for certain products are challenges.

    Management acknowledged

  • Customer caution in building inventories

    medium

    Customers are cautious, leading to increased timing for order fulfillment despite consistent quantities.

    Management acknowledged

  • Potential US tariffs

    low

    Management believes potential tariffs would be manageable for their specific products, as there are no significant US producers of their exports.

    Both downplayed

Q&A highlights

8 direct
Specialty chemicals growth drivers Direct
No, actually new products have not yet been introduced. There is still some work is going on. But it is largely due to little better demand that we are seeing in specific couple of products. And basically, the end-use application of the customer is seeing also higher demand.

Clarifies that current growth in specialty chemicals is primarily from improved demand for existing products, not new product launches.

Asked by Nirav Jimudia

Specialty chemicals margin profile compared to other segments Direct
Not really. I mean, in polymer also, there are reasonably good margin products, and there are also normal margin products. So it's a kind of mix and match. For example, in case of polymers, as you are already aware, there are certain products where we have a formula-driven pricing. So margin remains constant.

Corrects the perception that specialty chemicals inherently have higher margins, explaining that profitability is a mix across all segments, with some polymer products having stable, good margins.

Asked by Nirav Jimudia

Progress on diversification into new non-acid/alkyl chloride products Direct
Right now, we are working on three products of that category... with one customer, we believe... that product will start to gradually go on stream for us around April or May and it will be a very small quantity to start with. But eventually it will see a significant revenue coming from that one particular product.

Provides a clear timeline for the commercialization of new, higher-value products, indicating future revenue streams.

Asked by Nirav Jimudia

Potential revenue and margins from new non-acid chloride products Direct
If everything goes right, then about 3-4 products when you put together in another 2 years' time, at the completion of 2 years, it would be annually anywhere between Rs. 150 crores-Rs. 200 crores. It would be around EBITDA margins of 20% roughly.

Quantifies the significant revenue potential and margin profile of the new products under development, providing a long-term growth outlook.

Asked by Ishan Thakkar

Current capacity utilization levels Direct
About 65%.

Offers a key operational metric, indicating that the company has substantial unused capacity (35%) to support future growth without immediate large-scale capital expenditure.

Asked by Richa

Impact of potential US tariffs under Trump's regime Direct
So far as our products are concerned, we have no, I mean to the best of our knowledge, there is no significant producer of the products that we are exporting to US... all these scenarios, whatever scenarios that we have internally run, they all look manageable in terms of sustaining our business in US.

Addresses a significant macro-economic risk, with management indicating that their specific product portfolio is less exposed and they have contingency plans.

Asked by Richa

Update on inorganic growth opportunities Direct
Some of them were good but highly overpriced... some of them were that we looked at were not fitting into our ethos or in our value system... So, far we have not yet zeroed onto any anything which would appeal to us from all aspects.

Explains the company's cautious and disciplined approach to M&A, prioritizing strategic fit and reasonable valuations over rapid expansion.

Asked by Richa

Timeline for NSE listing Direct
We believe that it should be done by April end

Provides a specific and near-term timeline for the completion of the NSE listing, a long-awaited corporate action.

Asked by Rohit Mehta

3 min read 6 chapters

Detailed narrative

Q3 FY25 Financial Performance and Market Context

Transpek Industry Limited reported a total revenue of ₹505.6 crores for the nine months of FY25, marking a 12% year-on-year growth. EBITDA for the period stood at ₹90.3 crores, a 7.6% increase YoY, excluding an exceptional loss of ₹6.9 crores from discarding obsolete equipment. The EBITDA margin was 17.9%, a 70 basis points reduction compared to 9M FY24, while Profit After Tax declined by 10.4% to ₹29.5 crores. Management acknowledged that the Indian and global chemical industry has faced multiple challenges, including soft demand in major global markets like China and Europe, and volatility in chemical prices.

Segmental and Geographical Revenue Contribution

The Polymer segment continued to be the largest revenue contributor, accounting for over 58% of the total. Specialty chemicals contributed 19%, and Pharma contributed 10%. Geographically, International Business was the primary driver, making up 86% of the revenue, with North America alone contributing over 62% of this international share. The remaining 14% of business came from the domestic market. The company emphasized that its performance should be assessed on an annual basis due to the nature of its business.

New Product Development and Diversification Strategy

Transpek is actively developing new non-acid/alkyl chloride products, with three currently in advanced stages. One product is expected to begin commercial supplies around April or May, gradually ramping up. These new products are projected to generate an annual revenue of ₹150-200 crores within two years, with an estimated EBITDA margin of 20%. The company follows a cautious approach to capital expenditure, investing only when there is clear demand visibility, and leverages its R&D capabilities for in-house technology development.

Capacity Utilization and Future Growth

The current capacity utilization stands at approximately 65%, providing significant headroom for growth without immediate large-scale greenfield investments. Management indicated that existing facilities can be converted and utilized for new products during their initial ramp-up phases. Future capacity expansion, whether within existing facilities or through new plants, will be considered once new products achieve a critical mass in terms of volume, likely in 1.5 to 2 years.

DuPont Partnership and Kevlar EXO Impact

Transpek maintains a strong relationship with DuPont, with a 10-year contract whose renewal discussions are anticipated in 1-1.5 years. Management expects to sustain current supply volumes. DuPont's new product, Kevlar EXO, an upgraded version of Kevlar, is expected to enter large-scale commercial production by January 2026. This development is projected to lead to a slight increase in demand for Transpek's raw materials, as Kevlar EXO is expected to have a higher consumption per unit of production.

NSE Listing and Inorganic Growth Outlook

The company has initiated the process for NSE listing and is in the final stages of submitting additional documents, with completion expected by April end. Regarding inorganic growth, Transpek has evaluated several opportunities but has not proceeded due to high valuations or a lack of strategic fit with its core values and sustainability practices. The company remains committed to finding opportunities that offer meaningful value addition and align with its ethos.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls